Insider Selling: Natera (NASDAQ:NTRA) CFO Sells $188,575.52 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 784 shares of the business’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $240.53, for a total transaction of $188,575.52. Following the transaction, the chief financial officer directly owned 63,339 shares in the company, valued at approximately $15,234,929.67. The trade was a 1.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Michael Burkes Brophy also recently made the following trade(s):

• On Thursday, January 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The stock was sold at an average price of $230.40, for a total transaction of $430,156.80.
• On Wednesday, January 28th, Michael Burkes Brophy sold 2,413 shares of Natera stock. The shares were sold at an average price of $237.56, for a total transaction of $573,232.28.
• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50.
• On Tuesday, January 20th, Michael Burkes Brophy sold 23,948 shares of Natera stock. The shares were sold at an average price of $234.74, for a total transaction of $5,621,553.52.

Natera Stock Performance

NTRA opened at $231.14 on Friday. The stock has a market capitalization of $31.97 billion, a PE ratio of -100.93 and a beta of 1.62. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36. The business’s 50 day moving average price is $235.91 and its 200 day moving average price is $194.11.

Natera (NASDAQ:NTRA) last posted its earnings results on Friday, November 7th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative return on equity of 25.07% and a negative net margin of 14.61%.The business had revenue of $592.18 million for the quarter, compared to analyst estimates of $514.55 million. During the same period last year, the business earned ($0.26) EPS. Natera’s revenue was up 34.7% compared to the same quarter last year. As a group, equities research analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on NTRA shares. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. Stephens increased their price objective on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. BTIG Research lifted their target price on shares of Natera from $230.00 to $260.00 and gave the company a “buy” rating in a report on Friday, December 5th. TD Cowen restated a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Finally, Wells Fargo & Company raised their price target on Natera from $190.00 to $205.00 and gave the stock an “equal weight” rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $249.20.

Institutional Investors Weigh In On Natera

A number of hedge funds have recently bought and sold shares of NTRA. Rakuten Investment Management Inc. purchased a new position in Natera in the third quarter worth approximately $34,096,000. SWS Partners grew its stake in shares of Natera by 11.8% during the third quarter. SWS Partners now owns 47,037 shares of the medical research company’s stock worth $7,572,000 after purchasing an additional 4,980 shares in the last quarter. Vontobel Holding Ltd. increased its holdings in Natera by 192.5% in the third quarter. Vontobel Holding Ltd. now owns 8,531 shares of the medical research company’s stock valued at $1,373,000 after buying an additional 5,614 shares during the last quarter. Baird Financial Group Inc. raised its stake in Natera by 277.8% in the second quarter. Baird Financial Group Inc. now owns 26,624 shares of the medical research company’s stock valued at $4,498,000 after buying an additional 19,576 shares in the last quarter. Finally, Orion Porfolio Solutions LLC lifted its holdings in Natera by 68.8% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 12,140 shares of the medical research company’s stock worth $2,051,000 after buying an additional 4,946 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced completion of enrollment in the randomized ACES‑EMB heart‑transplant trial — a clinical milestone for the transplant franchise (Prospera) that de‑risks the program’s pathway to clinical readouts and potential uptake. Article Title
• Positive Sentiment: Wall Street coverage remains largely favorable: multiple firms maintain buy/outperform views and several have raised targets (MarketBeat summary shows consensus around a “Moderate Buy” and an average target near $249). This supports upside expectations if results and growth continue.
• Neutral Sentiment: Natera reported preliminary Q4 revenue (details in the alert). Preliminary figures may influence sentiment when the final quarter report and guidance are released; investors should watch the formal Q4 release for confirmation versus consensus. Preliminary Q4 Revenue
• Neutral Sentiment: Institutional ownership remains extremely high (~99.9%), which tends to stabilize the shareholder base but can also concentrate selling/Buying flows when large holders move. (Source: MarketBeat summary.) Institutional Data
• Negative Sentiment: Multiple insider sales by senior executives: CFO Michael Burkes Brophy sold several tranches (totaling 5,064 shares across Jan. 20–29) and CEO Steven Chapman sold several thousand shares (roughly 5,970 shares across Jan. 27–28). These trades total millions of dollars and may create short‑term selling pressure despite insiders retaining large residual stakes. CFO Form 4 CEO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold smaller tranches. While each reduction is under ~1% of those insiders’ holdings, the cluster of sales amplifies negative signaling to the market. Fesko Form 4 Moshkevich Form 4

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.